The future of drug development: advancing clinical trial design

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nature reviews. Drug discovery

• Publication date

  2009-12-01

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1038/nrd3025PMID 19816458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spending on new drug development1.

  2010cited by this paper
• Use of canakinumab in the cryopyrin-associated periodic syndrome.

  2009cited by this paper
• Simulation-based sequential Bayesian design

  2007cited by this paper
• The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals.

  2007cited by this paper
• Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop

  2007cited by this paper
• Flexible Design and Efficient Implementation of Adaptive Dose-Finding Studies

  2007cited by this paper
• Model‐based Drug Development

  2007cited by this paper
• Adaptive trial design.

  2007cited by this paper
• Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials

  2007cited by this paper
• Bayesian Statistics

  2006cited by this paper
• Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts

  2006cited by this paper
• Bayesian clinical trials

  2006cited by this paper
• Large-Sample Bayesian Posterior Distributions for Probabilistic Sensitivity Analysis

  2006cited by this paper
• Adaptive, group sequential and decision theoretic approaches to sample size determination

  2006cited by this paper
• Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group

  2006cited by this paper
• Estimating the cost of new drug development: is it really 802 million dollars?

  2006cited by this paper
• The need for more efficient trial designs

  2006cited by this paper
• Sample Size Reestimation: A Review and Recommendations

  2006cited by this paper
• Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers

  2005cited by this paper
• Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

  2005cited by this paper
• How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

  2005cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Opinion: Prospects for productivity

  2004cited by this paper
• The price of innovation: new estimates of drug development costs.

  2003cited by this paper
• New estimates of drug development costs.

  2003cited by this paper
• On the inefficiency of the adaptive design for monitoring clinical trials

  2003cited by this paper
• Pharmacokinetic/pharmacodynamic modeling in drug development.

  2000cited by this paper
• Industrial perspective.

  2000cited by this paper
• Simulation of clinical trials.

  2000cited by this paper
• An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development

  1997cited by this paper
• Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development

  1997cited by this paper
• Review and Recommendations

  1983cited by this paper
• Rebuilding Big Pharma ’ s Business Model

  year unknowncited by this paper

• The Evolution of Chemical Biology into Translational Physiology and Precision Medicine.

  2025cites this paper
• Microfluidic single‐cell technologies for immunotherapeutic target discovery: From design concepts to preclinical applications

  2025cites this paper
• On the application of artificial intelligence in virtual screening

  2025cites this paper
• A seamless phase II/III design with dose optimization for oncology drug development

  2024cites this paper
• Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

  2024cites this paper
• Construct prognostic models of multiple myeloma with pathway information incorporated

  2024cites this paper
• Identifying and overcoming challenges in the EMA’s qualification of novel methodologies: a two-year review

  2024cites this paper
• Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV.

  2024cites this paper
• Designing a Data Science simulation with MERITS: A Primer

  2024cites this paper
• Generative models for wearables data

  2023cites this paper
• The Role of fMRI in Drug Development: An Update.

  2023cites this paper
• Better by design: What to expect from novel CAR-engineered cell therapies?

  2022cites this paper
• Advances in the Adverse Effects of Covid-19 Vaccination and the Concept of Vaccine Development

  2022cites this paper
• A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal Trials

  2021cites this paper
• Biomarkers

  2021cites this paper
• A comprehensive review on the application of artificial intelligence in drug discovery.

  2021cites this paper
• Influence of the COVID-19 Pandemic on Clinical Trial Discontinuation in Anesthesiology: Cross-sectional Analysis

  2021cites this paper
• Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development

  2020cites this paper
• Sphingolipid metabolism as a marker of hepatotoxicity in drug-induced liver injury.

  2020cites this paper
• Concurrent isolation of hepatic stem cells and hepatocytes from the human liver

  2020cites this paper
• In vitro evaluation of anti-fungal activity of tropicamide against strains of Candida spp. resistant to fluconazole in planktonic and biofilm form.

  2020cites this paper
• Cucurbitacin Mediated Regulation of Deregulated Oncogenic Signaling Cascades and Non-coding RNAs in Different Cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways.

  2020cites this paper
• Improving Clinical Trial Design in Gastrointestinal Oncology

  2019cites this paper
• Innovation in Oncology Drug Development

  2019cites this paper
• Decision-Making in Sequential Adaptive Clinical Trials, with Implications for Drug Misclassification and Resource Allocation

  2019cites this paper
• Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development.

  2019cites this paper
• The role of fMRI in drug development.

  2018cites this paper
• Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry

  2018cites this paper
• Trial Termination and Drug Misclassification in Sequential Adaptive Clinical Trials

  2018cites this paper
• Future of Drug Discovery: Bayesian Pharmacokinetic Modeling

  2018cites this paper
• Managing Expectations in the Transition to Proof of Concept Studies.

  2017cites this paper
• The Development of an Automated, Fluorescent, Quantitative Three-Dimensional In Vitro Organotypic Invasion Assay

  2017cites this paper
• The role of adaptive trial designs in drug development

  2017cites this paper
• Evaluation of Broad Anti-Herpesviral Activity with a-Hydroxytropolones

  2017cites this paper
• Analysis of integrated clinical trial protocols in early phases of medicinal product development

  2017cites this paper
• The Burden of the “False‐Negatives” in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures

  2017cites this paper
• Future Challenges in the Generation of Hepatocyte-Like Cells From Human Pluripotent Stem Cells

  2017cites this paper
• Nanomechanically Visualizing Drug-Cell Interaction at the Early Stage of Chemotherapy.

  2017cites this paper
• Title Systems biology embedded target validation : improvingefficacy in drug discovery

  2017cites this paper
• Classification of advanced stages of Parkinson’s disease: translation into stratified treatments

  2017cites this paper
• Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation.

  2017cites this paper
• Drug development for breast, colorectal, and non–small cell lung cancers from 1979 to 2014

  2017cites this paper
• Virtual Clinical Trials: A tool for the Study of Transmission of Nosocomial Infections

  2017cites this paper
• Strategies for Derisking Translational Processes for Biomedical Technologies.

  2017cites this paper
• Electrical Responses and Spontaneous Activity of Human iPS-Derived Neuronal Networks Characterized for 3-month Culture with 4096-Electrode Arrays

  2016cites this paper
• On the exfoliating polymeric cellular dosage forms for immediate drug release.

  2016cites this paper
• Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology.

  2016cites this paper
• Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery.

  2016cites this paper
• The Evolution of Clinical Development: From Technical Success to Clinical Value Creation

  2016cites this paper
• Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project

  2016cites this paper
• Changing the Paradigm for the Treatment and Development of New Therapies for FSGS

  2016cites this paper
• “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives

  2016cites this paper
• Contributions to the development and validation of fMRI-based biomarkers for drug discovery in social anxiety disorder

  2016cites this paper
• Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended‐Release and Long‐Acting Injectable Paliperidone

  2016influential citation
• The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system

  2016cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 223 Improved Methods for Pharmacometric Model-Based Decision-Making in Clinical Drug Development

  2016cites this paper
• An introduction to multiplicity issues in clinical trials: the what, why, when and how.

  2016cites this paper
• The discovery and development of Eg5 inhibitors for the clinic

  2015cites this paper
• Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire Responses

  2015cites this paper
• TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging

  2015cites this paper
• Regulators and industry tackle dose-finding issues

  2015cites this paper
• An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

  2015cites this paper
• Clinical trials of interventional oncology—moving from efficacy to outcomes

  2015cites this paper
• What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?

  2015cites this paper
• Melt-processed polymeric cellular dosage forms for immediate drug release.

  2015cites this paper
• Discontinued dermatological drugs in 2014

  2015cites this paper
• New ways to image and target tumour hypoxia and its molecular responses.

  2015cites this paper
• Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives.

  2015influential citation
• Developing a Framework to Manage a Pharmaceutical Innovation Ecosystem: Collaboration Archetypes, Open Innovation Tools, and Strategies

  2015cites this paper
• Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium

  2015cites this paper
• Quantitative PCR in the assessment of novel hepatic cell models

  2015cites this paper
• Algorithms for multi-armed bandit problems

  2014cites this paper
• Benchmarks for detecting ‘breakthroughs’ in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation

  2014cites this paper
• INHANCE: An Adaptive Confirmatory Study with Dose Selection at Interim

  2014cites this paper
• Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging.

  2014cites this paper
• Applications of NMR techniques: Hyphenations (LC-SPENMR), affinity (DOSY) and NOE based (STD and Tr-OESY) to probe the binding interactions of ligands (synthetic and natural) towards protein

  2014cites this paper
• Practical Considerations for a Two-Stage Confirmatory Adaptive Clinical Trial Design and Its Implementation: ADVENT Trial

  2014cites this paper
• Value‐Driven Drug Development: Unlocking the Value of Your Pipeline

  2014cites this paper
• Impact of Modeling and Simulation: Myth or Fact?

  2014cites this paper
• Evaluation of Strategies for the Phase II to Phase III Progression in Treatment Discovery

  2014cites this paper
• Metabolism-oriented Lead Optimization of Propargyl-linked DHFR Inhibitors

  2014cites this paper
• Effector Cells and Mechanisms in Chronic Spontaneous Urticaria

  2014cites this paper
• A Case Study for Adaptive Trial Design Consideration and Implementation

  2014cites this paper
• Approaches for Clinical Supply Modelling and Simulation

  2014cites this paper
• The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development

  2014cites this paper
• Systems biology‐embedded target validation: improving efficacy in drug discovery

  2014cites this paper
• Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond

  2014cites this paper
• Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements

  2013cites this paper
• Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

  2013cites this paper
• A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials

  2013cites this paper
• Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials

  2013cites this paper
• An Analytical Approach to Assess the Predictive Value of Biomarkers in Phase II Decision Making

  2013cites this paper
• Comparisons of Analysis Methods for Proof-of-Concept Trials

  2013cites this paper
• Modeling Human Liver Biology Using Stem Cell-Derived Hepatocytes

  2013cites this paper
• Developing High‐Fidelity Hepatotoxicity Models From Pluripotent Stem Cells

  2013cites this paper
• Priorities for improving drug research, development and regulation

  2013cites this paper
• A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation

  2013cites this paper
• Monitoring in clinical trials: benefit or bias?

  2013cites this paper
• Power of Rare Diseases: Found in Translation

  2013cites this paper
• Investigation of Characteristics of Japanese Clinical Trials in Terms of Data Variability

  2013cites this paper